Biotech Co.* (Country/Symbol)

Biotech Co.* (Country/Symbol)

Product

Disclosed Funding (M)

Terms/Details (Date)


Avid Bio-
services Inc.
(unit of Peregrine
Pharmaceuticals
Inc.; PPHM)

Inhibitex
Inc.*

Therapeutic monoclonal antibodies

ND

Manufacturing and supply agreement for antibodies that will be used in future clinical studies (3/19)

Eos Biotech-
nology
Inc.*

ICOS Corp.
(ICOS)

CHEF1 enhanced mammalian protein expression technology

ND

A manufacturing and licensing agreement in which ICOS will produce Eos' lead monoclonal antibody candidate to clinical specifications for use in Phase I/II trials for the treatment of cancer (1/9)

GenOdyssee
SA
(France)*

Transgenomic
Inc.
(TBIO)

Nucleic acid analysis services

ND

Service provider agreement in which Transgenomic will market and sell nucleic acid analysis services that will be performed by GenOdyssee Genetics, a division of GenOdyssee (1/9)

Inhibitex
Inc.*

Nabi Inc.
(NABI)

INH-A21

ND

Manufacturing agreement for 10 years for Inhibitex's lead product, INH-A21, at Nabi's Boca Raton facility (12/6)

PPD Discovery
(subsidiary of
PPD Inc.; PPDI)

New England
Biolabs Inc.*
and Cypex Ltd.
(Scotland)*

Recombinant human cytochrome P450 enzymes

ND

New England Biolabs will produce and sell CYP450 enzymes under the Pharmazyme trademark and will pay PPD royalties; PPD also made an agreement for Cypex to manufacture, market and distribute P450 using the Pharmazyme technology (3/22)

Seradyn Inc.
(unit of Apogent
Technologies
Inc.; NYSE:
AOT)

Avid Bio-
services Inc.
(unit of Peregrine
Pharmaceuticals
Inc.; PPHM)

Raw material for a therapeutic drug monitoring kit

ND

Supply agreement in which Avid will manufacture the raw material for the kit distributed by Seradyn (3/6)

VaxGen Inc.
(VXGN)

Celltrion Inc.
(South Korea)*

AidsVax

$120

The companies will invest $120M to build and operate a facility in Incheon, South Korea, to manufacture AidsVax; the venture also will fund a smaller facility in South San Francisco; VaxGen will provide mammalian cell culture technology and biologics production expertise to Celltrion, but no cash, in exchange for a 44% interest in the joint venture (2/25)


Notes:

# The information in the chart does not cover agricultural agreements; * Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the Nasdaq market

ND = Not disclosed, reported and/or available; NYSE = New York Stock Exchange